Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 88 | 2024 | 11097 | 2.450 |
Why?
|
Radiosurgery | 18 | 2024 | 1330 | 1.600 |
Why?
|
Brachytherapy | 20 | 2018 | 1220 | 1.540 |
Why?
|
Prostate-Specific Antigen | 30 | 2023 | 2463 | 1.190 |
Why?
|
Prostate | 16 | 2023 | 1761 | 0.860 |
Why?
|
Androgen Antagonists | 10 | 2022 | 1412 | 0.830 |
Why?
|
Adenocarcinoma | 19 | 2020 | 6360 | 0.780 |
Why?
|
Nitriles | 4 | 2021 | 980 | 0.720 |
Why?
|
Phenylthiohydantoin | 1 | 2021 | 206 | 0.640 |
Why?
|
Rectum | 10 | 2018 | 898 | 0.530 |
Why?
|
Prostatectomy | 19 | 2024 | 1786 | 0.520 |
Why?
|
Carcinoma, Transitional Cell | 4 | 2023 | 790 | 0.510 |
Why?
|
Benzamides | 1 | 2021 | 1376 | 0.490 |
Why?
|
Carcinoma, Renal Cell | 7 | 2024 | 3186 | 0.430 |
Why?
|
Kidney Neoplasms | 8 | 2024 | 4282 | 0.430 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2016 | 798 | 0.410 |
Why?
|
Hyperthermia, Induced | 5 | 2010 | 414 | 0.400 |
Why?
|
Iodine Radioisotopes | 3 | 2006 | 1029 | 0.380 |
Why?
|
Urinary Bladder Neoplasms | 4 | 2023 | 2186 | 0.340 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2006 | 1677 | 0.330 |
Why?
|
Tosyl Compounds | 3 | 2008 | 115 | 0.320 |
Why?
|
Erectile Dysfunction | 8 | 2018 | 437 | 0.310 |
Why?
|
Dysuria | 1 | 2007 | 6 | 0.300 |
Why?
|
Anilides | 3 | 2008 | 413 | 0.290 |
Why?
|
Goserelin | 1 | 2008 | 126 | 0.280 |
Why?
|
Urination Disorders | 3 | 2014 | 236 | 0.280 |
Why?
|
Leuprolide | 2 | 2008 | 313 | 0.270 |
Why?
|
Quality of Life | 12 | 2024 | 13485 | 0.270 |
Why?
|
Radiation Injuries | 4 | 2011 | 1196 | 0.250 |
Why?
|
Amifostine | 2 | 2002 | 39 | 0.250 |
Why?
|
Antineoplastic Agents, Hormonal | 9 | 2008 | 1536 | 0.240 |
Why?
|
Radiation-Protective Agents | 2 | 2002 | 87 | 0.240 |
Why?
|
Radiotherapy Dosage | 14 | 2018 | 2915 | 0.240 |
Why?
|
Male | 99 | 2024 | 364203 | 0.240 |
Why?
|
Ultrasonography, Interventional | 2 | 2013 | 1523 | 0.240 |
Why?
|
Radiotherapy | 10 | 2018 | 1500 | 0.230 |
Why?
|
Radiotherapy, High-Energy | 5 | 2000 | 228 | 0.210 |
Why?
|
Neoplasm Staging | 21 | 2023 | 11217 | 0.200 |
Why?
|
Biopsy, Needle | 2 | 2009 | 1615 | 0.190 |
Why?
|
Prostheses and Implants | 3 | 2008 | 1275 | 0.190 |
Why?
|
Aged | 56 | 2024 | 171319 | 0.190 |
Why?
|
Pattern Recognition, Automated | 2 | 2004 | 987 | 0.190 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2023 | 1759 | 0.180 |
Why?
|
Rectal Diseases | 2 | 2013 | 141 | 0.180 |
Why?
|
Gynecomastia | 1 | 2021 | 88 | 0.170 |
Why?
|
Drugs, Chinese Herbal | 1 | 2002 | 146 | 0.170 |
Why?
|
Humans | 109 | 2024 | 767040 | 0.170 |
Why?
|
Glomerular Filtration Rate | 3 | 2024 | 2227 | 0.170 |
Why?
|
Prosthesis Implantation | 1 | 2004 | 594 | 0.170 |
Why?
|
Androgens | 3 | 2021 | 1281 | 0.170 |
Why?
|
Disease-Free Survival | 8 | 2022 | 6844 | 0.170 |
Why?
|
Body Fat Distribution | 1 | 2021 | 246 | 0.160 |
Why?
|
Middle Aged | 55 | 2024 | 223233 | 0.160 |
Why?
|
Urinary Bladder | 7 | 2023 | 1155 | 0.160 |
Why?
|
Aged, 80 and over | 24 | 2024 | 59548 | 0.160 |
Why?
|
Selenium | 1 | 2002 | 418 | 0.160 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2002 | 617 | 0.150 |
Why?
|
Medical Errors | 1 | 2006 | 1260 | 0.140 |
Why?
|
Vitamin E | 1 | 2002 | 872 | 0.140 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2004 | 1233 | 0.140 |
Why?
|
Patient Satisfaction | 5 | 2013 | 3488 | 0.140 |
Why?
|
Surgery, Computer-Assisted | 1 | 2004 | 996 | 0.130 |
Why?
|
Nomograms | 1 | 2018 | 236 | 0.130 |
Why?
|
Organs at Risk | 1 | 2018 | 367 | 0.130 |
Why?
|
Follow-Up Studies | 19 | 2024 | 39317 | 0.130 |
Why?
|
Artifacts | 1 | 2004 | 1904 | 0.130 |
Why?
|
Magnetic Resonance Imaging | 7 | 2016 | 36582 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 9410 | 0.110 |
Why?
|
Cystectomy | 3 | 2023 | 603 | 0.110 |
Why?
|
Boron Neutron Capture Therapy | 2 | 2004 | 51 | 0.110 |
Why?
|
Antioxidants | 1 | 2002 | 1671 | 0.110 |
Why?
|
Algorithms | 2 | 2004 | 14098 | 0.110 |
Why?
|
Benchmarking | 1 | 2020 | 1056 | 0.110 |
Why?
|
Antigens, Neoplasm | 2 | 1992 | 1997 | 0.110 |
Why?
|
Risk | 2 | 2021 | 9606 | 0.110 |
Why?
|
Watchful Waiting | 2 | 2021 | 492 | 0.110 |
Why?
|
Kidney | 4 | 2024 | 7063 | 0.110 |
Why?
|
Lymphatic Irradiation | 2 | 1990 | 115 | 0.100 |
Why?
|
Orchiectomy | 2 | 2006 | 466 | 0.100 |
Why?
|
Urinary Incontinence | 4 | 2024 | 490 | 0.100 |
Why?
|
Time Factors | 10 | 2024 | 40154 | 0.100 |
Why?
|
Salvage Therapy | 3 | 2023 | 1271 | 0.100 |
Why?
|
Penile Erection | 2 | 2011 | 100 | 0.100 |
Why?
|
Finasteride | 3 | 2004 | 86 | 0.100 |
Why?
|
Quality Assurance, Health Care | 3 | 2010 | 2174 | 0.100 |
Why?
|
Radiotherapy, Computer-Assisted | 2 | 2006 | 90 | 0.100 |
Why?
|
Combined Modality Therapy | 6 | 2010 | 8535 | 0.100 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2016 | 1126 | 0.090 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2004 | 3370 | 0.090 |
Why?
|
Urinary Catheterization | 2 | 2014 | 195 | 0.090 |
Why?
|
Body Composition | 1 | 2021 | 2454 | 0.090 |
Why?
|
Lymphatic Metastasis | 7 | 2022 | 2900 | 0.090 |
Why?
|
Imaging, Three-Dimensional | 1 | 2004 | 4052 | 0.090 |
Why?
|
Actuarial Analysis | 3 | 1996 | 370 | 0.090 |
Why?
|
Testosterone | 1 | 2021 | 2490 | 0.080 |
Why?
|
Tumor Burden | 1 | 2016 | 1903 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 4 | 2016 | 20741 | 0.080 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2003 | 409 | 0.080 |
Why?
|
Retrospective Studies | 19 | 2024 | 81659 | 0.080 |
Why?
|
Radiotherapy, Conformal | 5 | 2005 | 548 | 0.080 |
Why?
|
Treatment Outcome | 17 | 2024 | 65295 | 0.080 |
Why?
|
Decision Support Techniques | 2 | 2009 | 2006 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2023 | 1788 | 0.070 |
Why?
|
Stereotaxic Techniques | 2 | 2017 | 551 | 0.070 |
Why?
|
Transvestism | 1 | 2006 | 4 | 0.070 |
Why?
|
Boron | 2 | 2004 | 37 | 0.070 |
Why?
|
Ultrasonography | 3 | 2006 | 6000 | 0.070 |
Why?
|
Medical Oncology | 2 | 2020 | 2341 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 935 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2003 | 876 | 0.070 |
Why?
|
Referral and Consultation | 3 | 2014 | 3618 | 0.070 |
Why?
|
Self Report | 2 | 2015 | 3773 | 0.060 |
Why?
|
Phantoms, Imaging | 2 | 2004 | 2487 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5446 | 0.060 |
Why?
|
Reproducibility of Results | 7 | 2020 | 20169 | 0.060 |
Why?
|
Analysis of Variance | 3 | 2013 | 6215 | 0.060 |
Why?
|
Neoadjuvant Therapy | 3 | 2023 | 2902 | 0.060 |
Why?
|
Radiation Dosage | 2 | 2006 | 1965 | 0.060 |
Why?
|
Meningioma | 1 | 1994 | 1219 | 0.060 |
Why?
|
Quality-Adjusted Life Years | 2 | 2008 | 1741 | 0.060 |
Why?
|
Spinal Neoplasms | 2 | 1992 | 714 | 0.060 |
Why?
|
Meningeal Neoplasms | 1 | 1994 | 1253 | 0.060 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2023 | 48 | 0.060 |
Why?
|
Evaluation Studies as Topic | 1 | 2006 | 1623 | 0.050 |
Why?
|
Ultrasonic Therapy | 2 | 2005 | 216 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2013 | 2232 | 0.050 |
Why?
|
Radiation Injuries, Experimental | 1 | 2003 | 88 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2020 | 4881 | 0.050 |
Why?
|
Prospective Studies | 12 | 2024 | 54886 | 0.050 |
Why?
|
Multivariate Analysis | 8 | 2012 | 12069 | 0.050 |
Why?
|
Mercaptoethylamines | 1 | 2002 | 4 | 0.050 |
Why?
|
Radiation Pneumonitis | 1 | 2003 | 100 | 0.050 |
Why?
|
Fructose | 1 | 2004 | 284 | 0.050 |
Why?
|
Morbidity | 1 | 2008 | 1754 | 0.050 |
Why?
|
Telangiectasis | 1 | 2002 | 78 | 0.050 |
Why?
|
Administration, Rectal | 1 | 2002 | 69 | 0.050 |
Why?
|
Flutamide | 2 | 2003 | 95 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2022 | 3552 | 0.050 |
Why?
|
Respiration | 1 | 2008 | 1655 | 0.050 |
Why?
|
Robotics | 1 | 2008 | 807 | 0.050 |
Why?
|
Biopsy | 6 | 2019 | 6777 | 0.050 |
Why?
|
Movement | 1 | 2008 | 1473 | 0.050 |
Why?
|
Data Collection | 1 | 2010 | 3321 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2516 | 0.050 |
Why?
|
Lymph Node Excision | 3 | 2022 | 1267 | 0.050 |
Why?
|
Ibuprofen | 1 | 2002 | 228 | 0.050 |
Why?
|
Bone Neoplasms | 5 | 2003 | 2563 | 0.050 |
Why?
|
Hypertension | 1 | 2021 | 8615 | 0.040 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2002 | 361 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2013 | 15424 | 0.040 |
Why?
|
Nitric Oxide Synthase | 1 | 2003 | 911 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 896 | 0.040 |
Why?
|
Administration, Topical | 1 | 2002 | 703 | 0.040 |
Why?
|
Survival Rate | 7 | 2013 | 12823 | 0.040 |
Why?
|
Fiducial Markers | 1 | 2021 | 134 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2004 | 14672 | 0.040 |
Why?
|
Age Factors | 5 | 2018 | 18401 | 0.040 |
Why?
|
Risk Assessment | 5 | 2021 | 24299 | 0.040 |
Why?
|
Urologic Diseases | 1 | 2002 | 246 | 0.040 |
Why?
|
Bone Marrow | 1 | 1990 | 2926 | 0.040 |
Why?
|
Radiographic Image Enhancement | 1 | 2004 | 877 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2011 | 3561 | 0.040 |
Why?
|
Intraoperative Period | 1 | 2000 | 512 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2003 | 678 | 0.040 |
Why?
|
Cohort Studies | 9 | 2021 | 41718 | 0.040 |
Why?
|
Catheterization | 1 | 2004 | 1430 | 0.040 |
Why?
|
Tyrosine | 1 | 2003 | 1425 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3854 | 0.040 |
Why?
|
Glioblastoma | 2 | 2004 | 3461 | 0.040 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 2270 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1733 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6513 | 0.040 |
Why?
|
Disease Progression | 3 | 2016 | 13646 | 0.040 |
Why?
|
Radiometry | 1 | 2004 | 818 | 0.040 |
Why?
|
Equipment Design | 1 | 2006 | 3489 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 1992 | 2930 | 0.040 |
Why?
|
Needles | 1 | 2021 | 461 | 0.040 |
Why?
|
Complementary Therapies | 1 | 2002 | 487 | 0.040 |
Why?
|
Adult | 14 | 2022 | 223317 | 0.040 |
Why?
|
Intestinal Diseases | 2 | 2015 | 505 | 0.040 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 1999 | 414 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2004 | 1458 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2013 | 8940 | 0.040 |
Why?
|
Penis | 1 | 2018 | 209 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2015 | 364 | 0.030 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 1997 | 80 | 0.030 |
Why?
|
Endosonography | 1 | 2021 | 626 | 0.030 |
Why?
|
Kallikreins | 1 | 2018 | 219 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2006 | 5311 | 0.030 |
Why?
|
Doxorubicin | 1 | 2003 | 2229 | 0.030 |
Why?
|
Fecal Incontinence | 2 | 2013 | 246 | 0.030 |
Why?
|
Femur Head | 1 | 2018 | 297 | 0.030 |
Why?
|
Urethra | 1 | 2018 | 406 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2013 | 5363 | 0.030 |
Why?
|
Germany | 1 | 2017 | 882 | 0.030 |
Why?
|
Brain Neoplasms | 3 | 2004 | 9108 | 0.030 |
Why?
|
Survival Analysis | 4 | 2000 | 10092 | 0.030 |
Why?
|
Phosphoprotein Phosphatases | 1 | 1997 | 327 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2020 | 903 | 0.030 |
Why?
|
Survivors | 2 | 2020 | 2381 | 0.030 |
Why?
|
Computer Systems | 1 | 1996 | 468 | 0.030 |
Why?
|
Female | 14 | 2024 | 396660 | 0.030 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 1997 | 457 | 0.030 |
Why?
|
Logistic Models | 2 | 2023 | 13284 | 0.030 |
Why?
|
Regression Analysis | 6 | 2000 | 6331 | 0.030 |
Why?
|
Operating Rooms | 1 | 2000 | 790 | 0.030 |
Why?
|
Australia | 1 | 2017 | 1263 | 0.030 |
Why?
|
Immediate-Early Proteins | 1 | 1997 | 444 | 0.030 |
Why?
|
Contrast Media | 1 | 2007 | 5329 | 0.030 |
Why?
|
Intestines | 1 | 2022 | 1905 | 0.030 |
Why?
|
Helium | 1 | 1994 | 119 | 0.030 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12536 | 0.030 |
Why?
|
Japan | 1 | 2017 | 1418 | 0.030 |
Why?
|
Particle Accelerators | 1 | 1994 | 172 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14766 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 11872 | 0.030 |
Why?
|
Risk Factors | 5 | 2014 | 74886 | 0.030 |
Why?
|
In Situ Hybridization | 3 | 2003 | 1892 | 0.030 |
Why?
|
Lumbar Vertebrae | 3 | 1992 | 1885 | 0.030 |
Why?
|
Canada | 1 | 2017 | 2127 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 1997 | 1244 | 0.020 |
Why?
|
Pilot Projects | 4 | 2004 | 8732 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 2014 | 436 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2000 | 2428 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2002 | 3043 | 0.020 |
Why?
|
Enzyme Inhibitors | 2 | 2003 | 3726 | 0.020 |
Why?
|
International Cooperation | 1 | 2017 | 1434 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2022 | 3468 | 0.020 |
Why?
|
Kinetics | 2 | 2016 | 6287 | 0.020 |
Why?
|
Diarrhea | 1 | 1998 | 1319 | 0.020 |
Why?
|
Receptors, Androgen | 1 | 1997 | 1089 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.020 |
Why?
|
Odds Ratio | 2 | 2014 | 9660 | 0.020 |
Why?
|
Radiography | 3 | 2008 | 6975 | 0.020 |
Why?
|
Urethral Obstruction | 2 | 2003 | 56 | 0.020 |
Why?
|
Paper | 1 | 2010 | 80 | 0.020 |
Why?
|
Dysgerminoma | 1 | 1990 | 66 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2002 | 10748 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2000 | 2599 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 1999 | 2800 | 0.020 |
Why?
|
Pelvis | 2 | 1992 | 736 | 0.020 |
Why?
|
Urologic Surgical Procedures, Male | 1 | 2008 | 79 | 0.020 |
Why?
|
Patient Selection | 3 | 2012 | 4256 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1994 | 949 | 0.020 |
Why?
|
Prognosis | 6 | 2012 | 29963 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2008 | 13491 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2013 | 2920 | 0.020 |
Why?
|
Exhalation | 1 | 2008 | 185 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2000 | 12793 | 0.020 |
Why?
|
Forecasting | 2 | 2011 | 2936 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15925 | 0.020 |
Why?
|
Cost of Illness | 1 | 2016 | 1951 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 2008 | 286 | 0.020 |
Why?
|
Carcinoma | 1 | 1998 | 2326 | 0.020 |
Why?
|
Immunohistochemistry | 4 | 2003 | 11063 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 1990 | 1987 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 8048 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 951 | 0.020 |
Why?
|
Spouses | 1 | 2008 | 286 | 0.020 |
Why?
|
Postoperative Complications | 2 | 2008 | 15824 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 1997 | 3440 | 0.020 |
Why?
|
Fast Neutrons | 1 | 2004 | 18 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 6210 | 0.010 |
Why?
|
Gold | 1 | 2008 | 482 | 0.010 |
Why?
|
Melanoma | 1 | 2003 | 5702 | 0.010 |
Why?
|
Urology | 1 | 2008 | 384 | 0.010 |
Why?
|
Physicians | 2 | 2014 | 4593 | 0.010 |
Why?
|
Boron Compounds | 1 | 2004 | 195 | 0.010 |
Why?
|
Life Tables | 2 | 1994 | 367 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2016 | 10393 | 0.010 |
Why?
|
Choice Behavior | 1 | 2008 | 848 | 0.010 |
Why?
|
Radiation Oncology | 1 | 2008 | 572 | 0.010 |
Why?
|
Hodgkin Disease | 1 | 1990 | 1383 | 0.010 |
Why?
|
Ureteral Obstruction | 1 | 2004 | 293 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1993 | 4892 | 0.010 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2003 | 513 | 0.010 |
Why?
|
Digestive System | 1 | 2002 | 244 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22254 | 0.010 |
Why?
|
Neoplasms | 1 | 2010 | 22350 | 0.010 |
Why?
|
Aspirin | 1 | 2013 | 3135 | 0.010 |
Why?
|
Apoptosis | 1 | 1997 | 9513 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 13048 | 0.010 |
Why?
|
Paraffin | 1 | 1999 | 36 | 0.010 |
Why?
|
Tissue Embedding | 1 | 1999 | 43 | 0.010 |
Why?
|
Palliative Care | 2 | 1992 | 3641 | 0.010 |
Why?
|
Estrogens | 1 | 2006 | 1536 | 0.010 |
Why?
|
Boston | 1 | 2012 | 9360 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2004 | 1250 | 0.010 |
Why?
|
Internet | 1 | 2010 | 3114 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2008 | 2196 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2000 | 748 | 0.010 |
Why?
|
Linear Models | 1 | 2008 | 5875 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10582 | 0.010 |
Why?
|
Body Temperature | 1 | 2001 | 780 | 0.010 |
Why?
|
Seminal Vesicles | 1 | 1997 | 101 | 0.010 |
Why?
|
United States | 2 | 2017 | 72971 | 0.010 |
Why?
|
Dual Specificity Phosphatase 1 | 1 | 1997 | 43 | 0.010 |
Why?
|
Protons | 1 | 2002 | 1101 | 0.010 |
Why?
|
Polymerase Chain Reaction | 2 | 1997 | 6067 | 0.010 |
Why?
|
Protein Phosphatase 1 | 1 | 1997 | 135 | 0.010 |
Why?
|
Gene Amplification | 1 | 2000 | 1088 | 0.010 |
Why?
|
Temperature | 1 | 2002 | 2232 | 0.010 |
Why?
|
Sexuality | 1 | 1997 | 179 | 0.010 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 492 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 1997 | 474 | 0.010 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 1997 | 440 | 0.010 |
Why?
|
Genes, Tumor Suppressor | 1 | 1999 | 1058 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2000 | 2509 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2003 | 6226 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 1999 | 1119 | 0.010 |
Why?
|
Prostatic Hyperplasia | 1 | 1997 | 514 | 0.010 |
Why?
|
Immobilization | 1 | 1993 | 229 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1992 | 15 | 0.010 |
Why?
|
Strontium Radioisotopes | 1 | 1992 | 18 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 1997 | 7611 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 6106 | 0.010 |
Why?
|
Up-Regulation | 1 | 2000 | 4143 | 0.010 |
Why?
|
Treatment Failure | 1 | 1997 | 2658 | 0.010 |
Why?
|
Massachusetts | 1 | 2003 | 8890 | 0.010 |
Why?
|
Reference Values | 1 | 1997 | 4918 | 0.010 |
Why?
|
Lung | 1 | 2008 | 10076 | 0.010 |
Why?
|
Cell Division | 1 | 1997 | 4473 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 1997 | 3611 | 0.010 |
Why?
|
Affect | 1 | 1997 | 1494 | 0.000 |
Why?
|
Stress, Psychological | 1 | 2004 | 4526 | 0.000 |
Why?
|
Genetic Markers | 1 | 1994 | 2602 | 0.000 |
Why?
|
Gastrointestinal Diseases | 1 | 1997 | 1205 | 0.000 |
Why?
|
Double-Blind Method | 1 | 2002 | 12451 | 0.000 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2003 | 5332 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2000 | 8628 | 0.000 |
Why?
|
Gene Expression | 1 | 1997 | 7587 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2003 | 18330 | 0.000 |
Why?
|
Base Sequence | 1 | 1994 | 12414 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1994 | 17608 | 0.000 |
Why?
|
Adolescent | 1 | 1990 | 89046 | 0.000 |
Why?
|
Bone and Bones | 1 | 1992 | 2587 | 0.000 |
Why?
|
Models, Biological | 1 | 1994 | 9464 | 0.000 |
Why?
|
Pain | 1 | 1992 | 5101 | 0.000 |
Why?
|
Mice | 1 | 2003 | 81912 | 0.000 |
Why?
|
Incidence | 1 | 1992 | 21526 | 0.000 |
Why?
|
Animals | 1 | 2003 | 168965 | 0.000 |
Why?
|